Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 18/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3957278 | 0.79 | HSD11B1 (0.65) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL3596632 | 0.78 | HSD11B1 (0.61) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL3611474 | 0.78 | HSD11B1 (0.61) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL3608417 | 0.78 | HSD11B1 (0.61) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL752389 | 0.78 | HSD11B1 (0.64) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL4045444 | 0.78 | HSD11B1 (0.69) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL3613804 | 0.78 | HSD11B1 (0.61) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL3610751 | 0.78 | HSD11B1 (0.61) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL4045441 | 0.78 | HSD11B1 (0.69) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL13072515 | 0.78 | HSD11B1 (0.61) | HSD11B1KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138190-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | AMGEN INC. | 2009-07-09 | — | — | US | disclosed |
| US-7524848-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | GPR119, GLP1R, INSR | HSD11B1 2477/4885KCNH2 860/4885CYP3A4 888/4885 |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | GPR119, GLP1R, INSR | HSD11B1 2477/4885KCNH2 860/4885CYP3A4 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.